Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.

Scientific reports - 10 Oct 2024

Tan Gongxun, Jin Bingquan, Qian Xiaoqin, Wang Yuguo, Zhang Guoliang, Agyekum Enock Adjei, Wang Feng, Shi Liang, Zhang Yue, Mao Zhenwei, Shi Chunhe, Xu Ying, Li Xiuying, Zhang Lele, Li Shaohua

Abstract excerpt

Telomerase reverse transcriptase promoter (TERTp) mutations are associated with non-radioiodine avidity. However, the role of these mutations in the clinical outcomes of patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) remains unknown. Herein, we aim to analyze gene mutations and clinical manifestations to verify TERTp's role in driving disease progression to RAIR-DTC and clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins B-raf

Share to Telomerase

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39390090
DOI: 10.1038/s41598-024-75087-9
PMCID: PMC11467215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.PMID 39390090Read ↗

TERT Promoter Mutations Contribute to Adverse Clinical Outcomes and Poor Prognosis in Radioiodine Refractory Differentiated Thyroid CancerSemantic proximity Read ↗

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.Semantic proximity Read ↗

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Semantic proximity Read ↗

Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.Semantic proximity Read ↗

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Semantic proximity Read ↗

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.Semantic proximity Read ↗

The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients.Semantic proximity Read ↗

Effect of BRAFV600E and TERT Promoter Mutations on Thyroglobulin Response in Patients With Distant-Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

TERT Promoter Mutations in Thyroid Cancer.Semantic proximity Read ↗

BRAF and TERT promoter mutations: clinical application in thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.